Abstract

A study of invasive strains of Streptococcus agalactiae (GBS) from Cordoba and Misiones, Argentina; was conducted to determine serotypes, the susceptibility to macrolides and molecular profiles of virulence and resistance. We studied 17 strains, recovered from cerebrospinal fluid, blood and cellulite and, a strain of trophoblastic remnants from Misiones. The serotypes were determined by agglutination with sera and phenotypes of resistance to macrolide-lincosamide-streptogramin B (MLSB), were determined with the double-disk test (D-test). The confirmation was performed by E-test by ERI and CLI respectively that determined the minimum inhibitory concentration (MIC). Results were interpreted as recommended by the Clinical and Laboratory Standards Institute (CLSI) 2013. Resistance genes: ermB, ermTR and mefA and the virulence genes: bac, bca, rib, lmb, hylB, scpB, fbsA, fbsB and cylB were investigated by conventional PCR. Serotype III (50%) and Ia (50%) were detected in Cordoba. One strain showed cMLSB phenotype, confirmed by MIC. The same strains showed a resistance gene ermB. All studied virulence genes were detected in 100% of these strains. In Misiones, serotypes were III (72.7%), Ia (18.2%) and Ib (9.1%). All strains were susceptible to CLI and ERI by D-test, confirmed by MIC. None of the strains showed resistance genes. Virulence genes bca, rib, hylB, lmb, fbsA, fbsB and cylB were detected in 100% of the strains, bac in 81.8% and scpB in 90.9%. Our results are in accordance with international data, associating higher frequency of serotype III of invasive neonatal disease followed by Ia. The presence of serotype Ib could indicate a regional difference for Misiones. We highlight the macrolides susceptibility in strains of Misiones and consistency in the results for D-test, MIC and PCR for the single strain resistant phenotype cMLSB from Cordoba. The virulence genes studied were presented with high frequency as expected for invasive strains.

Highlights

  • Streptococcus agalactiae (Lancefield group B streptococcal, GBS), initially described by Nocarrd and Mollereau in 1887 [1] was isolated from vaginal cultures in 1935, was listed as a human pathogen for the first time in 1938 as cause of fatal puerperal fever [2]

  • GBS strains of Misiones: The 11 strains were susceptible to ERI and CLI by disk test (D-test) and confirmation by CIM gave similar results with ranges from 0.003 to 0.12 μg/ml for ERI and from 0.032 to 0.094 μg/ml for CLI

  • GBS strains of Cordoba: Two strains belonging to the same patient and isolated from different clinical specimens, showed resistance phenotype cMLSB (ERI and CLI = 6 mm) confirmed by CIM (ERI and CLI = 8 μg/ml) for both strains, indicating that it is insulated with antibiotype identical

Read more

Summary

Introduction

Streptococcus agalactiae (Lancefield group B streptococcal, GBS), initially described by Nocarrd and Mollereau in 1887 [1] was isolated from vaginal cultures in 1935, was listed as a human pathogen for the first time in 1938 as cause of fatal puerperal fever [2]. Vaginal colonization rate in pregnant women is not equal between different geographical areas, the data world ranging from 5% to 30% [4], communicating data in the range of 1.4% to 18.15% for Argentina [5]. Published data for Misiones, a province of Argentina, show a colonization rate of 8.6% [6]. About 50% of babies born from these women are colonized with GBS during labor and 1% develop a severe infection [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.